Cargando…

Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5

Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or i...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Seyeon, Son, Myeongjoo, Park, Chul-Hyun, Jang, Ji Tae, Son, Kuk Hui, Byun, Kyunghee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460451/
https://www.ncbi.nlm.nih.gov/pubmed/32727125
http://dx.doi.org/10.3390/md18080393
_version_ 1783576604619833344
author Oh, Seyeon
Son, Myeongjoo
Park, Chul-Hyun
Jang, Ji Tae
Son, Kuk Hui
Byun, Kyunghee
author_facet Oh, Seyeon
Son, Myeongjoo
Park, Chul-Hyun
Jang, Ji Tae
Son, Kuk Hui
Byun, Kyunghee
author_sort Oh, Seyeon
collection PubMed
description Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or intimal hyperplasia. The purpose of this study was to evaluate whether pyrogallol-phloroglucinol-6,6-bieckol (PPB) from E. cava reduces VSMC proliferation and phenotype switching via the CCL5/CCR5 pathway. The CCL5/CCR5 expression, VSMC proliferation and phenotypic alterations were evaluated using a cell model of VSMC exposed in hyperlipidemia, and an animal model of mice fed a high-fat-diet (HFD). The expression of CCL5/CCR5 increased in both the cell and animal models of hyperlipidemia. Treatment with PPB decreased CCL5/CCR5 expression in both models. The expression of contractile markers of VSMCs, including alpha-smooth muscle actin (α-SMA), smooth muscle myosin heavy chain (SM-MHC), and smooth muscle protein 22 alpha (SM22α), were decreased by hyperlipidemia and restored after treatment with PPB. The silencing of CCR5 attenuated the effects of PPB treatment. VSMC proliferation and the intima-media thickness of the aortas, increased with HFD and decreased after treatment with PPB. The VSMC proliferation ratio and messenger ribonucleic acid (mRNA) expression of cell cycle regulatory factors increased in the in vitro model and were restored after treatment with PPB. PPB treatment reduced VSMC proliferation and phenotype switching induced by hyperlipidemia through inhibition of the CCL5/CCR5 pathway.
format Online
Article
Text
id pubmed-7460451
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74604512020-09-03 Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 Oh, Seyeon Son, Myeongjoo Park, Chul-Hyun Jang, Ji Tae Son, Kuk Hui Byun, Kyunghee Mar Drugs Article Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or intimal hyperplasia. The purpose of this study was to evaluate whether pyrogallol-phloroglucinol-6,6-bieckol (PPB) from E. cava reduces VSMC proliferation and phenotype switching via the CCL5/CCR5 pathway. The CCL5/CCR5 expression, VSMC proliferation and phenotypic alterations were evaluated using a cell model of VSMC exposed in hyperlipidemia, and an animal model of mice fed a high-fat-diet (HFD). The expression of CCL5/CCR5 increased in both the cell and animal models of hyperlipidemia. Treatment with PPB decreased CCL5/CCR5 expression in both models. The expression of contractile markers of VSMCs, including alpha-smooth muscle actin (α-SMA), smooth muscle myosin heavy chain (SM-MHC), and smooth muscle protein 22 alpha (SM22α), were decreased by hyperlipidemia and restored after treatment with PPB. The silencing of CCR5 attenuated the effects of PPB treatment. VSMC proliferation and the intima-media thickness of the aortas, increased with HFD and decreased after treatment with PPB. The VSMC proliferation ratio and messenger ribonucleic acid (mRNA) expression of cell cycle regulatory factors increased in the in vitro model and were restored after treatment with PPB. PPB treatment reduced VSMC proliferation and phenotype switching induced by hyperlipidemia through inhibition of the CCL5/CCR5 pathway. MDPI 2020-07-27 /pmc/articles/PMC7460451/ /pubmed/32727125 http://dx.doi.org/10.3390/md18080393 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oh, Seyeon
Son, Myeongjoo
Park, Chul-Hyun
Jang, Ji Tae
Son, Kuk Hui
Byun, Kyunghee
Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
title Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
title_full Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
title_fullStr Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
title_full_unstemmed Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
title_short Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
title_sort pyrogallol-phloroglucinol-6,6-bieckolon attenuates vascular smooth muscle cell proliferation and phenotype switching in hyperlipidemia through modulation of chemokine receptor 5
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460451/
https://www.ncbi.nlm.nih.gov/pubmed/32727125
http://dx.doi.org/10.3390/md18080393
work_keys_str_mv AT ohseyeon pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5
AT sonmyeongjoo pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5
AT parkchulhyun pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5
AT jangjitae pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5
AT sonkukhui pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5
AT byunkyunghee pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5